CJC-1295: Evidence, Safety, Dosing Context, and Access

CJC-1295 is a synthetic growth hormone-releasing hormone analog studied for its effect on growth hormone and IGF-1 signaling. Human research is limited and mostly measures hormone markers, not proven outcomes like fat loss, muscle gain, recovery, or longer life. We have not verified FDA approval for CJC-1295 for these uses. Chia does not offer CJC-1295.

What it is

CJC-1295 is a synthetic peptide and long-acting growth hormone-releasing hormone analog. It was developed to stimulate the growth hormone-releasing factor receptor on the anterior pituitary, which can increase growth hormone and insulin-like growth factor 1, also called IGF-1 1, 12.

The names can be confusing. CJC-1295 with DAC usually means a version designed to last longer in the body through drug-affinity complex technology, while Modified GRF(1-29) is often discussed as a shorter-acting GHRH fragment in peptide communities; patients often search both terms together, but they are not the same clinical evidence base 1, 12.

In plain language, CJC-1295 is a signal peptide. It does not replace growth hormone; it pushes the body’s own GH/IGF-1 axis upstream. That difference matters because the published human trials mainly studied hormone signaling, not long-term health outcomes 1, 2, 6.

Mechanism of action

CJC-1295 acts on the growth hormone-releasing hormone pathway. In human studies, it was associated with prolonged stimulation of growth hormone and IGF-1 secretion, which are the main measured markers in the CJC-1295 evidence base 1.

Growth hormone-releasing hormone signaling

Growth hormone-releasing hormone, often shortened to GHRH, tells the pituitary gland to release growth hormone. Animal research identified CJC-1295 as a long-lasting growth hormone-releasing factor analog that activated the GRF receptor on the anterior pituitary in rats, which is animal evidence and should not be read as proof of human benefit 12.

Growth hormone and IGF-1: what the studies measured

The key human trial measured growth hormone and IGF-1 secretion after CJC-1295 exposure in healthy adults, and a related clinical trial reported that pulsatile GH secretion persisted during continuous stimulation with CJC-1295 1, 2. A later human primary study evaluated serum protein profile changes after GH/IGF-1 axis activation by CJC-1295 in normal adult subjects 6.

DAC vs non-DAC: why half-life matters

Half-life means how long a substance remains active in the body. CJC-1295 was designed as a long-acting analog, so exposure can last longer than shorter GHRH fragments; that is why DAC vs non-DAC naming matters when people compare CJC-1295 with Modified GRF(1-29) online 1, 12.

A longer signal is not automatically better or safer. The same mechanism that can raise GH and IGF-1 markers can also raise safety questions in people with conditions affected by fluid balance, glucose metabolism, or hormone-sensitive disease; the available CJC-1295 literature is not large enough to settle those questions 1, 5, 9.

Evidence

CJC-1295 has evidence grade B for the quantity and design of published evidence supplied for this page. That grade reflects limited human clinical research, including one randomized controlled trial and another human clinical trial, not proof of safety or real-world benefit 1, 2.

The strongest human evidence is the Teichman et al. randomized controlled trial in healthy adults, which studied CJC-1295 as a long-acting GHRH analog and measured GH and IGF-1 secretion 1. Another clinical trial by Ionescu and Frohman reported that pulsatile GH secretion persisted during continuous stimulation with CJC-1295 2.

These studies can support a narrow statement: CJC-1295 has been studied in humans for GH and IGF-1 signaling. They do not prove that CJC-1295 causes meaningful weight loss, increases muscle in healthy people, improves athletic recovery, or extends human lifespan 1, 2, 5, 9.

A terminated Phase 2 trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, with a planned enrollment of 120 participants, but a terminated registry entry should not be used as proof of clinical benefit 13. That matters for patients searching CJC-1295 for visceral obesity or weight loss.

CJC-1295 also appears in sports, bodybuilding, and doping-related literature. Analyses of seized doping material and reviews of peptide use can show that these substances circulate outside normal medical channels, but they do not establish therapeutic benefit for patients 8, 10, 11.

If you want more background, our guides to CJC-1295 peptide therapy, CJC-1295 peptide basics, and peptide side effects explain how to read early peptide evidence without treating it as a promise.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.

Reported dosing ranges

CJC-1295 dosing in this section means doses reported in studies or registries, not instructions for use. Study dosing should not be copied by patients because trial design, screening, monitoring, peptide identity, and safety rules do not match online self-use 1, 13.

Online forums often compress all of this into simple-looking dosing charts. That is risky. The published human evidence does not establish a patient protocol, and product identity can be uncertain when material comes from non-clinical peptide sellers 10, 11.

Legal status

Our regulatory log holds no confirmed federal action for CJC-1295. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.

Safety

CJC-1295 safety is not settled by the small human evidence base. The same studies that describe GH and IGF-1 stimulation were not designed to prove long-term safety for weight loss, performance, recovery, or longevity use 1, 2, 5.

Reported and plausible risks from growth hormone and IGF-1 stimulation

Because CJC-1295 acts through the GH/IGF-1 axis, clinicians think about risks linked to excess or prolonged GH/IGF-1 signaling, including fluid-related symptoms, glucose-metabolism concerns, and hormone-sensitive conditions. The CJC-1295 literature supplied here does not provide enough long-term human outcome data to quantify those risks for patients 1, 5, 9.

Reviews of unapproved peptide therapies in sports medicine and endocrine or metabolic contexts stress that early mechanistic or biomarker data should not be treated as proof of broad clinical benefit. That is especially important when a peptide is being promoted for recovery, body composition, or anti-aging without strong outcome trials 3, 4, 5, 9.

Why product quality and source matter

Product source is a safety issue, not a small detail. Doping-material studies have identified growth hormone secretagogues in seized materials, and internet-use research has described CJC-1295 use outside routine clinical systems; those sources raise concerns about identity, impurity, sterility, and lack of medical monitoring 10, 11.

Material labeled “research use only” is not made for patient treatment. It may not come with the same clinical review, prescription controls, sterile handling standards, or pharmacy accountability that patients should expect in medical care 7, 8, 10.

Who should talk to a clinician before considering any GH-axis peptide?

Anyone with diabetes or blood-sugar problems, active or past cancer, pituitary disease, severe sleep apnea, edema, carpal-tunnel symptoms, pregnancy, or complex medication use should talk with a clinician before considering GH-axis peptide care. This caution comes from the biologic role of GH and IGF-1 signaling and the limited long-term CJC-1295 safety data, not from a proven safe-use pathway 1, 5, 9.

Interactions

CJC-1295 interaction studies are not well established in the supplied human literature. That is not the same as saying there are no interactions; it means no strong published interaction evidence is available here to reassure patients 1, 2, 5.

Medications and conditions that may affect risk

A clinician would be especially careful when a patient uses glucose-lowering medication, hormone-related therapy, corticosteroids, or other agents that affect fluid balance or endocrine signaling. The reason is mechanistic: CJC-1295 is studied through GH and IGF-1 effects, and GH/IGF-1 signaling can intersect with glucose and hormone pathways 1, 6, 9.

Labs and follow-up a clinician may consider

Depending on the person, a clinician may consider baseline and follow-up review of symptoms, medications, glucose markers, IGF-1, and other endocrine context. The CJC-1295 studies measured hormone and protein markers, so monitoring conversations should be individualized rather than copied from online peptide protocols 1, 2, 6.

How to obtain it legally

CJC-1295 access should start with a clinical conversation, not a shopping cart. A safer process means a licensed clinician reviews your health history, medications, goals, contraindications, and monitoring needs before deciding whether any peptide or hormone-related care is appropriate.

Chia does not offer CJC-1295, and we do not present it as a Chia treatment. Naming that clearly is part of being useful: if a compound is not in our current catalog, we treat it as education-only.

For treatments Chia does offer, our model is 100% online: a short health questionnaire, review by a licensed US provider, prescribing only where clinically appropriate, dispensing through state-licensed 503A compounding pharmacies, home delivery, and patient-portal messaging between visits. A prescription is never guaranteed, and compounded drugs are not FDA-approved.

For patients asking about GH-axis options, Chia offers Sermorelin as injection, nasal spray, and tablets, with plans currently starting at $179/month for injection. Chia also offers the Weight + Muscle protocol, which includes Sermorelin Injection plus a choice of GLP-1, from $329/month; these are separate offerings and should not be confused with CJC-1295.

If you are comparing peptide information online, start with source quality. Our guide to finding a legitimate peptide source explains why licensed medical evaluation matters more than forum dosing charts, and our comparison of CJC-1295, Ipamorelin, and Sermorelin explains why Reddit can be useful for questions but not for prescribing decisions.

Keep reading

Peptides

CJC-1295 No DAC Peptide: Modified GRF 1-29, Evidence, Risks, and Safer Questions to Ask

Peptides

CJC-1295 and Ipamorelin Dosage Calculator: What Online Tools Can and Cannot Tell You

Peptides

Tesamorelin vs CJC-1295: Evidence, Uses, and Safety Differences